Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib and Venetoclax in Relapsed/Refractory CLL, SLL, or Richter's Syndrome
NCT03534323Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of duvelisib, venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter syndrome (RS), sponsored by Dana-Farber Cancer Institute. Started Jul 2018; status: completed.
02
Drugs
duvelisibvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT03534323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03534323.